Vaccine Value Profile for Schistosomiasis

Featured News

The GW VRU Director, Dr. David Diemert, co-authored an article assessing the value of public health, economic, and societal value of developing a vaccine to prevent and reduce the transmission of Schistosomiasis. Endemic in 78 countries, it is estimated that approximately 236 million people were treated for Schistosomiasis in 2019. This article evaluates the global public health need for a vaccine.

Click here to read the article.

Latest News

Pfizer's RSV vaccine, Abrysvo, has shown a strong immune response and well-tolerated safety profile in new study.
Our Deputy Director, Dr. Elissa Malkin, was a part of the Pfizer's newest study on its respiratory syncytial virus (RSV) vaccine, Abrysvo, which has shown to have a strong immune response in adults 18+.
Young child smiling with his armed raised. There is a band-aid are the arm to indicate that he has received a vaccination.
Check out the CDC's new report titled 'Health and Economic Benefits of Routine Childhood Immunizations in the Era of the Vaccines for Children Program - United States, 1994 - 2023
The CDC has released a new report on the health and economic benefits of routine childhood immunizations since the creation of the Vaccines for Children (VFC) program in 1994.
Individuals of all ages smiling. Vaccines help protect you throughout your life. Talk to a healthcare provider you trust about staying up to date on recommended vaccines.
August is National Immunization Awareness Month
It's National Immunization Awareness Month! Getting vaccinated on the recommended schedule is an important part of protecting against many diseases. Please check with your trusted provider to see what vaccines are recommended for you!